To the full analysis
ResMed stock: growth
RMDResMed reported $5.65B in revenue for fiscal 2026, up 9.9% on the prior year, up 12.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
11.5%
per year from 2007 to 2026, per share 11.8%
Earnings (Annual rate)
17.9%
per year from 2007 to 2026, per share 18.3%
Free cash flow (Annual rate)
28.8%
per year from 2007 to 2026, per share 29.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 12.1% | 11.9% | 11.5% |
| Revenue per share | 12.2% | 11.5% | 11.8% |
| Earnings | 26.3% | 15.8% | 17.9% |
| Earnings per share | 26.1% | 15.3% | 18.3% |
| Free cash flow | 21.6% | 13.1% | 28.8% |
| Free cash flow per share | 21.7% | 12.8% | 29.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $716.33M | $66.3M | $13.55M |
| 2008 | $835.4M | $110.3M | $62.06M |
| 2009 | $920.74M | $146.45M | $124.66M |
| 2010 | $1.09B | $190.09M | $126.57M |
| 2011 | $1.24B | $226.99M | $208.19M |
| 2012 | $1.37B | $254.85M | $322.05M |
| 2013 | $1.51B | $307.13M | $331.04M |
| 2014 | $1.55B | $345.27M | $310.11M |
| 2015 | $1.68B | $352.89M | $311.24M |
| 2016 | $1.84B | $352.41M | $480.1M |
| 2017 | $2.07B | $342.28M | $342.58M |
| 2018 | $2.34B | $315.59M | $433.57M |
| 2019 | $2.61B | $404.59M | $381.71M |
| 2020 | $2.96B | $621.67M | $696.32M |
| 2021 | $3.2B | $474.51M | $619.89M |
| 2022 | $3.58B | $779.44M | $195.11M |
| 2023 | $4.22B | $897.56M | $559.3M |
| 2024 | $4.69B | $1.02B | $1.29B |
| 2025 | $5.15B | $1.4B | $1.66B |
| 2026 | $5.65B | $1.52B | $1.65B |
Revenue by segment
How ResMed Inc. makes its money and how that has shifted. Names are as the company reports them.
- Sleep And Respiratory88%
- Software As Service12%
Figures as a table
| 2021 | 2022 | 2023 | 2024 | Share 2024 | |
|---|---|---|---|---|---|
| Sleep And Respiratory | $2.82B | $3.18B | $3.73B | $4.1B | 87.5% |
| Software As Service | $373.59M | $400.83M | $497.98M | $584.13M | 12.5% |
| Total revenue | $3.2B | $3.58B | $4.22B | $4.69B | 100% |
Revenue by region
Where ResMed Inc. generates its revenue.
- U [S]$3.0B64%
- Global$1.7B36%
The company split earlier years differently. A history would not be comparable, so only 2024 is shown.
Figures as a table
| 2024 | Share 2024 | |
|---|---|---|
| U [S] | $2.98B | 63.6% |
| Global | $1.71B | 36.4% |
| Total revenue | $4.69B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2023)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.